AI Article Synopsis

Article Abstract

Objectives: To develop a reliable HPLC method for the simultaneous determination of plasma tryptophan, kynurenine and 5-hydroxytryptamine to analyze tryptophan metabolism.

Design And Methods: Separation was carried out on a C8 column with the mobile phase composed of acetate buffer (pH 4.5) and acetonitrile using theophylline as internal standard. The eluates were monitored by ultraviolet detection with programmed wavelength.

Results: Analysis was achieved in less than 8.0min. The limits of quantification were 3.97μmol/L, 4.36nmol/L and 0.421μmol/L for tryptophan, 5-hydroxytryptamine and kynurenine, respectively. Reproducibility and recovery were satisfactory. Twenty healthy adults and 20 uremic patients undergoing hemodialysis were analyzed using the present method. Tryptophan metabolism was found to be disturbed in uremic patients and was improved obviously after hemodialysis.

Conclusions: The developed HPLC method is simple, reliable and suitable for monitoring tryptophan metabolism in uremic patients undergoing hemodialysis.

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.clinbiochem.2010.10.011DOI Listing

Publication Analysis

Top Keywords

uremic patients
16
patients undergoing
12
undergoing hemodialysis
12
simultaneous determination
8
tryptophan kynurenine
8
kynurenine 5-hydroxytryptamine
8
hplc method
8
tryptophan metabolism
8
tryptophan
6
determination tryptophan
4

Similar Publications

Background: Patients on maintenance hemodialysis (HD) face complications due to the accumulation of protein-bound uremic toxins, such as advanced glycation end products (AGEs), which contribute to inflammation, oxidative stress, and cardiovascular disease. Conventional HD techniques inadequately remove AGEs. This study evaluates the efficacy of the HA130 hemoadsorption cartridge combined with high-flux HD (HF-HD) in enhancing AGE removal.

View Article and Find Full Text PDF

Shiga toxin-producing Escherichia coli (STEC) infections pose a significant public health challenge, characterized by severe complications including hemolytic uremic syndrome (HUS) due to Shiga toxin (Stx) production. Current therapeutic approaches encounter a critical limitation, as conventional antibiotic treatment is contraindicated due to its propensity to trigger bacterial SOS response and subsequently enhance Stx production, which increases the likelihood of developing HUS in antibiotic-treated patients. The lack of effective, safe therapeutic options has created an urgent need for alternative treatment strategies for STEC infections.

View Article and Find Full Text PDF

Clinical efficacy and safety of sodium thiosulfate in the treatment of uremic pruritus: a meta-analysis of randomized controlled trials.

Arch Dermatol Res

January 2025

Blood Purification Center, Zhejiang Hospital, 1229 Gudun Road, Xihu District, Hangzhou, Zhejiang, 310030, China.

Uremic pruritus (UP) is a debilitating condition frequently associated with chronic kidney disease, severely impairing patients' quality of life and contributing to increased mortality. Recent studies have suggested that intravenous sodium thiosulfate (STS) may offer therapeutic relief for pruritus in patients undergoing hemodialysis. To assess its effectiveness, we conducted a systematic review and meta-analysis to explore the potential of intravenous STS in managing UP.

View Article and Find Full Text PDF

Metabolomics provides powerful tools that can inform about heterogeneity in disease and response to treatments. In this exploratory study, we employed an electrochemistry-based targeted metabolomics platform to assess the metabolic effects of three randomly-assigned treatments: escitalopram, duloxetine, and Cognitive-Behavioral Therapy (CBT) in 163 treatment-naïve outpatients with major depressive disorder. Serum samples from baseline and 12 weeks post-treatment were analyzed using targeted liquid chromatography-electrochemistry for metabolites related to tryptophan, tyrosine metabolism and related pathways.

View Article and Find Full Text PDF

Complement-mediated thrombotic microangiopathy (TMA) in the form of atypical hemolytic uremic syndrome (aHUS) has emerged as an immune complication of systemic adeno-associated virus (AAV) gene transfer that was unforeseen based on nonclinical studies. Understanding this phenomenon in the clinical setting has been limited by incomplete data and a lack of uniform diagnostic and reporting criteria. While apparently rare based on available information, AAV-associated TMA/aHUS can pose a substantial risk to patients including one published fatality.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!